What Is MFN?
A Most Favored Nation (MFN) drug pricing policy would tie certain U.S. drug prices (most likely within Medicare) to the lowest price paid for the same product in a basket of comparable, economically advanced countries.
Rather than relying solely on domestic benchmarks such as Average Sales Price (ASP), MFN models use international reference pricing (IRP) to cap U.S. reimbursement levels
While MFN is not currently in effect, variations of the policy have been proposed multiple times and remain a recurring theme in federal drug pricing discussions. In a post-IRA environment where Medicare negotiation is already reshaping pricing dynamics, MFN represents a potential next phase of pricing reform.
Why MFN Matters for Market Access
MFN is not simply a pricing policy. It fundamentally changes the interplay between global pricing strategy and U.S. access dynamics.
Historically:
- U.S. pricing has been largely insulated from international pricing decisions
- Market access strategy in the U.S. focused primarily on payer mix, contracting, and value demonstration domestically
Under MFN:
- Global pricing decisions directly influence U.S. reimbursement
- Ex-U.S. launch sequencing and pricing strategy become U.S. access decisions
- Market access planning must shift from domestic optimization to global coordination
This creates both operational complexity and strategic risk.
Key Market Access Impacts
1. Global Launch Sequencing Becomes a U.S. Access Lever
If U.S. Medicare reimbursement is pegged to the lowest international price:
- Early lower-price agreements in EU markets could reduce U.S. reimbursement ceilings
- Delays in ex-U.S. launches may become more common
- Manufacturers may prioritize price stability over speed to global access
Market Access Implication:
Launch sequencing, traditionally a commercial strategy decision, becomes a critical component of U.S. access preservation.
2. Increased Pressure on Gross-to-Net Strategy
MFN could effectively cap top-line pricing:
- Reduced flexibility to offset domestic rebates with higher list prices
- Potential compression of net revenue if international reference prices are significantly lower
- Greater scrutiny of contracting structures across both Medicare and commercial segments
Market Access Implication:
Manufacturers will need tighter integration between pricing, contracting, and policy teams to manage cross-market impacts
3. Impact on Medicare Negotiation Leverage
If MFN is layered onto IRA price negotiation:
- The “maximum fair price” ceiling could be influenced by international pricing floors
- Negotiation dynamics may shift toward even greater federal leverage
- Therapeutic classes with strong ex-U.S. HTA pressure (e.g., oncology, immunology) could see disproportionate exposure
Market Access Implication:
Access teams must prepare for negotiations that incorporate international comparators more explicitly and aggressively.
4. Formulary and Utilization Management Ripple Effects
Lower Medicare reimbursement rates could:
- Change buy-and-bill economics in Part B
- Affect provider margin and prescribing behavior
- Influence payer formulary positioning in Part D
If margins compress:
- Providers may prefer alternative therapies with better economics
- Access hurdles may increase if plans attempt to offset reimbursement compression elsewhere.
Market Access Implication:
Manufacturer field reimbursement and provider engagement strategies will need to adapt quickly
Manufacturer Decision-Making Under MFN Risk
Even before implementation, MFN risk affects strategic planning. Manufacturers should be incorporating MFN into scenario modeling now
1. Portfolio Risk Stratification
Companies should assess:
- Which assets are most exposed to international price referencing?
- Which therapeutic areas face the largest EU-U.S. price deltas?
- Which products are most Medicare-dependent?
This enables:
- Prioritized mitigation planning
- Revenue-at-risk modeling
- Earlier lifecycle management interventions
2. Integrated Global Pricing Governance
MFN requires tighter alignment across:
- U.S. market access
- Global pricing & reimbursement
- Government affairs
- Legal and compliance
Decisions that were once siloed (e.g., a German price agreement) may have direct downstream U.S. impact
Prepared organizations will:
- Establish formal cross-market price governance committees
- Model international pricing agreements before execution
- Create scenario playbooks for reference price compression
3. Enhanced Economic Value Demonstration
As pricing ceilings tighten, value demonstration becomes even more critical:
- Stronger real-world evidence (RWE)
- More robust health economic modeling
- Outcomes-based contract readiness
- Clear differentiation from therapeutic alternatives
Under MFN, margin compression increases the importance of maintaining favorable access tiers and minimizing utilization restrictions.
4. Contracting Innovation and Risk Sharing
If top-line pricing flexibility narrows:
- Manufacturers may shift toward outcomes-based agreements
- Indication-specific pricing may gain traction
- Population health-based contracting could become more common
Access teams should be developing infrastructure now to support:
- Data collection and analytics
- Outcomes measurement
- Performance-based reimbursement models
5. Scenario Planning and Financial Modeling
MFN preparedness requires:
- Modeling various international basket configurations
- Estimating price floors under different country mixes
- Stress-testing gross-to-net assumptions
- Evaluating provider economics impact (especially in Part B)
This modeling should inform:
- Investor communications
- Portfolio prioritization
- Pipeline investment decisions
Preparedness Checklist for Market Access Teams
Manufacturers should consider the following actions:
Strategic Planning
☐ Conduct MFN exposure modeling by product
☐ Quantify Medicare revenue at risk
☐ Map international price differentials across key markets
Governance
☐ Formalize cross-market pricing review processes
☐ Establish escalation protocols before signing major ex-U.S. agreements
☐ Align U.S. and global access leadership
Evidence & Value
☐ Strengthen RWE generation plans
☐ Prepare enhanced HEOR dossiers
☐ Expand outcomes-based contracting readiness
Operational Readiness
☐ Assess provider reimbursement impact
☐ Update field reimbursement training
☐ Develop payer communication strategies
MFN may or may not materialize in its current form, but the direction of travel in U.S. drug pricing policy is clear: increased scrutiny, global benchmarking, and tighter reimbursement controls. Organizations that wait for final rules before acting risk being structurally unprepared.
Is your portfolio exposed to MFN risk?
At Danforth Health, we work with manufacturers to model policy exposure, align global and U.S. pricing strategy, pressure-test access assumptions, and build practical readiness plans. If MFN, or broader international reference pricing, would materially affect your portfolio, now is the time to assess your exposure and build a coordinated response.
Schedule a conversation with our experts to evaluate your MFN exposure and build a readiness strategy.
